To find out if taking a drug called infliximab (the "study drug") is safe and effective in reversing insulin dependence in CIADM.
New onset diabetes≥ 200 mg/dl and/or A1c ≥6.5 OR
Worsening glycemic control: requiring insulin per clinician assessment (fasting glucose or average glucose on CGM>20% and /or A1c >0.5% from prior to ICI use ) AND /OR
If Presenting with DKA/HHS: include if within 6 weeks of presentation AND
Must have detectable random c-peptide level 0.2 - 1 ng/mL with blood glucose of 145 mg/dl
Participants already on insulin for pre-existing type 1 or type 2 diabetes.
Participants with undetectable c-peptide levels i.e. <0.2 with blood glucose of 145 mg/dl or higher.
For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.